Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...
We recently published a list of 7 Best Nanotech Penny Stocks to Invest In. In this article, we are going to take a look at ...
NanoViricides, Inc. (NYSE American: NNVC) has filed its quarterly report for the period ending Dec. 31, 2024, with the SEC, reporting cash and cash e ...
SHELTON, Conn. (AP) — SHELTON, Conn. (AP) — NanoViricides Inc. (NNVC) on Friday reported a loss of $2 million in its fiscal second quarter. On a per-share basis, the Shelton, Connecticut-based ...
NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad-spectrum antiviral drug NV-387, a drug that the Bird Flu ...
(MENAFN- Investor Brand Network) NanoViricides, Inc. (NYSE American: NNVC) announced its broad-spectrum antiviral NV-387 as a potential solution for combating H5N1 bird flu, stating that the virus is ...
Shelton, Connecticut Thursday, February 13, 2025, 16:00 Hrs [IST] ...
SHELTON, CT / ACCESS Newswire / February 11, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") declared today that it is ready to fight the bird flu with its revolutionary broad ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results